FOLIA BIOLOGICA, published by Charles University Prague, First Faculty of Medicine, is an esteemed academic journal that has been contributing to the fields of Biochemistry, Cell Biology, Developmental Biology, Genetics, Immunology, and Molecular Biology since its inception in 1961. With an ISSN of 0015-5500, this journal serves as a vital platform for researchers and professionals to disseminate their findings and advance knowledge within these disciplines. Despite its current Category Quartiles ranking in the lower tiers (Q3 and Q4), FOLIA BIOLOGICA continues to provide valued insights and foster scholarly dialogue, particularly in its paralleled fields. The journal is headquartered in Prague, Czech Republic, and operates without Open Access options, which emphasizes its focus on curated, peer-reviewed content essential for academicians and students. By bridging theoretical and practical knowledge, FOLIA BIOLOGICA remains committed to enriching the scientific community and serving as a cornerstone for future research innovations.

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, published by PERGAMON-ELSEVIER SCIENCE LTD in the United Kingdom, serves as a leading interdisciplinary platform for the dissemination of pioneering research and reviews in the realms of Neuroscience, Behavioral Neuroscience, Cognitive Neuroscience, and Neuropsychology. With an impressive impact factor reflected in its Q1 ranking across multiple categories for 2023, the journal is recognized for its rigorous peer-reviewed content that influences the advancement of scientific knowledge in behavioral and cognitive research. An essential resource for researchers, professionals, and students alike, the journal emphasizes the exploration of complex neural mechanisms that underlie behavior and cognitive processes. Despite being a subscription-based publication, the journal's extensive archive from 1978 to 2024 fosters a wealth of knowledge designed to inspire and facilitate future advancements within the field.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, a premier academic journal published by TAYLOR & FRANCIS LTD, stands at the forefront of interdisciplinary research in the fields of Biological Psychiatry, Psychiatry, and Mental Health. Based in the United Kingdom, this esteemed journal (ISSN: 1562-2975; E-ISSN: 1814-1412) has become increasingly influential since its inception in 2000, with a remarkable impact factor that reflects its high-quality research contributions. The journal is consistently ranked in the Q1 and Q2 categories across various relevant indices, demonstrating its reputation for excellence within the academic community. With Scopus rankings placing it in the top 20th percentile for Psychiatry and Mental Health, the WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY serves as a vital resource for researchers, professionals, and students seeking to further their understanding of the intricate relationship between biological processes and psychiatric phenomena. Despite being a traditional access journal, it possesses a robust scope that encompasses groundbreaking studies, reviews, and advancements in the understanding of mental health disorders, underlining its importance as a key reference in the advancement of psychiatric science and therapeutic practices.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging is a leading interdisciplinary journal published by Elsevier, focusing on the convergence of biological psychiatry, cognitive neuroscience, and advanced neuroimaging techniques. With its prestigious Q1 rankings across essential categories such as Biological Psychiatry, Cognitive Neuroscience, and Neurology (clinical), this journal is at the forefront of research that examines the complexities of mental health through innovative methodologies. Covering a broad spectrum of topics from neurobiological mechanisms to clinical applications, it aims to provide a platform for scholars and practitioners to exchange insights on mental disorders and their neurobiological underpinnings. The impact factor and Scopus rankings further underscore its importance, with rankings highlighting its position in the top percentiles of related disciplines. By fostering an open exchange of ideas and promoting cutting-edge research, this journal is an essential resource for researchers, professionals, and students dedicated to advancements in the understanding and treatment of psychiatric and neurological conditions.

MOVEMENT DISORDERS, published by Wiley, stands as a premier outlet for cutting-edge research in the field of neurology, particularly focusing on the various aspects of movement disorders. With both its ISSN (0885-3185) and E-ISSN (1531-8257) identifiers, this journal is at the forefront of neurological research, holding a remarkable impact factor and recognized in the top quartiles (Q1) of the disciplines of Neurology and Clinical Neurology as of 2023. The journal boasts an impressive Scopus ranking, placing it in the top 8 out of 192 for Neuroscience-Neprology and 19 out of 400 for Medicine-Clinical Neurology, reflecting its high relevance and influence in the field. Released quarterly since its inception in 1986 and continuing through 2024, MOVEMENT DISORDERS publishes a mix of original research articles, reviews, and case reports that catalyze innovation and foster collaboration among researchers, healthcare professionals, and students dedicated to understanding and treating movement disorders. As a non-open access journal, it nevertheless offers valuable insights that are essential for the advancement of knowledge in neurology, making it a critical resource for anyone invested in this challenging and evolving field.

Frontiers in Psychiatry is a leading journal dedicated to advancing research within the field of psychiatry and mental health. Published by FRONTIERS MEDIA SA, the journal has established a commendable reputation since its inception, reflected in its Q1 status in the 2023 Psychiatry and Mental Health category and a robust ranking of 142 out of 567 in the Scopus database. With an open access model initiated in 2009, Frontiers in Psychiatry aims to disseminate high-quality research to a global audience, fostering collaboration and innovation among researchers, clinicians, and students alike. The journal covers a broad spectrum of topics, including neurobiology, psychosocial factors, treatments, and public health implications of mental disorders, ensuring comprehensive representation of contemporary psychiatric science. Located in Lausanne, Switzerland, and running until 2024, the journal not only emphasizes the importance of mental health research but also encourages interdisciplinary discourse, making it an essential resource for anyone invested in the well-being of individuals and communities alike.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

TRENDS IN NEUROSCIENCES, published by CELL PRESS, is a leading journal in the field of neuroscience, offering cutting-edge insights and important developments in the rapidly evolving landscape of brain research. With an impressive Impact Factor and ranking in the top quartile (Q1) of the category for Neuroscience (miscellaneous), it is positioned as a vital resource for researchers and professionals seeking to stay abreast of the latest discoveries and trends from 1978 to the present. Specifically ranked #3 out of 113 in General Neuroscience by Scopus, this journal promotes the interdisciplinary exchange of ideas and knowledge, making it an essential platform for students and experienced scholars alike. Although it is not an Open Access journal, its value lies in its rigorous peer-review process and commitment to maintaining the highest standards of academic integrity. By continuing to explore the complexities of neural processes and behavior, TRENDS IN NEUROSCIENCES plays a crucial role in shaping the future of neuroscience research and education.

Human Gene is an innovative open access journal published by ELSEVIER, dedicated to the ever-evolving field of genetics. Established in 2022, this journal serves as a vital resource for researchers, professionals, and students alike, aiming to facilitate the dissemination of groundbreaking research and advancements in both basic and clinical genetics. With an ISSN of 2773-0441, Human Gene focuses on providing a platform for high-quality studies that investigate genetic mechanisms, their implications in health and disease, and novel therapeutic strategies. The journal currently holds a Q4 ranking in both Genetics and Clinical Genetics categories, reflecting its emerging status within the scientific community, and strives to enhance its impact to better serve an engaged audience. With its base in Amsterdam, Netherlands, Human Gene is committed to making research accessible through its open access model, inviting contributions that advance our understanding of human genetics and foster collaboration across disciplines.